NaturemiRI

Executive Summary

NaturemiRI is a private biotechnology company based in Cambridge, USA, founded in 2020. The company specializes in developing plasmid-based microRNA (miRNA) inhibitors for both research and therapeutic applications. Its proprietary Plasmid-based MicroRNA Inhibitor System (PMIS) is designed to address the limitations of traditional miRNA inhibition, offering improved specificity and durability. Initially targeting genetic and RNA-driven diseases, NaturemiRI's platform has potential applications across oncology, metabolic disorders, and rare genetic conditions. While the company is still in early stages with no disclosed funding rounds or clinical-stage programs, its innovative approach positions it within the rapidly growing RNA therapeutics space. NaturemiRI's PMIS platform could enable long-term miRNA modulation without the need for repeated dosing, a key advantage over synthetic inhibitors. The company is reportedly advancing preclinical studies and may seek IND-enabling data within the next 12-18 months. Given the nascent stage, the risk profile is high, but the platform's versatility and the growing interest in miRNA-based therapies provide moderate upside. Conviction is tempered by the lack of public data on efficacy, safety, or financial backers. Key catalysts include preclinical data readouts, potential IND filings, and strategic partnerships for co-development or licensing.

Upcoming Catalysts (preview)

• Q4 2026Preclinical Data Readout for Lead miRNA Inhibitor Candidate40% success
• Q2 2027IND Submission for First Therapeutic Program30% success
• Q3 2026Research Collaboration with Academic or Pharma Partner50% success